Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- January31 2004
- Volume 11
- Issue 2
News You Can Use: Doctors Top in Wages
Advertisement
Apparently things aren't that bad. According to the most recent National Occupational Employment and Wage study conducted by the US Bureau of Labor Statistics (www.bls.gov), physicians earn the nation's highest mean annual wages. More than 750 occupations were included in the study. The following is a breakdown of the 10 highest earners in health care:
Articles in this issue
about 18 years ago
Understand the Fully Bundled Pensionsabout 18 years ago
Establish Year-Round Financial Planningabout 18 years ago
Understand the Expenses of Your Childabout 18 years ago
Learn the Secrets of Wilbur and Orvilleabout 18 years ago
Get the New Year Off to an Excellent Startabout 18 years ago
Don't Outlive Your Retirement Nest Eggabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Does Med School Affect Malpractice?about 18 years ago
With Asset Protection, Compliance Is Keyabout 18 years ago
Read a Pair of Classic Investment TomesAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5